Effect of platelet inhibition with cangrelor during PCI on ischemic events.

DL, Bhatt; GW, Stone; KW, Mahaffey; CM, Gibson; PG, Steg; CW, Hamm; MJ, Price; S, Leonardi; D, Gallup; E, Bramucci; PW, Radke; P, Widimský; F, Tousek; J, Tauth; D, Spriggs; BT, McLaurin; DJ, Angiolillo; P, Généreux; T, Liu; J, Prats; M, Todd; S, Skerjanec; HD, White; RA, Harrington

doi:10.1056/nejmoa1300815

Public

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Shared by NobleBlocks on Mar 10, 2013 • 12:00 AM UTC

Authors:

Bhatt DL

Stone GW

Mahaffey KW

Abstract

Background The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects.M...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!